2024
Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Craiglow B, Lee Y, Vañó-Galván S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen Y, Mostaghimi A. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatology And Therapy 2024, 14: 1959-1968. PMID: 38904749, PMCID: PMC11265044, DOI: 10.1007/s13555-024-01208-x.Peer-Reviewed Original ResearchSymptoms of anxietyQuality of lifeDomain scoresHealth-related quality of lifeMeasures of quality of lifeMeasures of HRQoLHealth-related qualityBaricitinib 2 mgSALT scoreBaricitinib 4 mgPsychosocial distressAssociated with improvementsHair regrowthAA scaleMethodsThis post hoc analysisHRQoLDose of baricitinibInterquartile rangePhase III trialsResultsIn totalSevere alopecia areataPost hoc analysisDisease associated with high ratesDepressionScores
2023
Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Piraccini B, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen Y, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials. JEADV Clinical Practice 2023, 3: 242-248. DOI: 10.1002/jvc2.269.Peer-Reviewed Original ResearchSevere alopecia areataSymptoms of anxietyHealth-related qualityAlopecia areataWeek 36Hair regrowthAutoimmune hair loss disorderPsychological burdenBackground Alopecia areataProportion of patientsPhase 3 trialSelective Janus kinase 1JAK-2 inhibitorHair loss disorderBaricitinib 2Nonresponder imputationMethods PatientsHADS scoresMore patientsLarge trialsHospital AnxietyDepression ScaleAA symptomsPsychosocial distressAnalysis of covarianceWhen to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
King B, Shapiro J, Ohyama M, Egeberg A, Piraccini B, Craiglow B, Sinclair R, Chen Y, Wu W, Ding Y, Somani N, Dutronc Y. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. British Journal Of Dermatology 2023, 189: 666-673. PMID: 37708254, DOI: 10.1093/bjd/ljad253.Peer-Reviewed Original ResearchSevere alopecia areataBaricitinib-treated patientsPhase III trialsAlopecia areataResponder subgroupBaricitinib 4Hair regrowthIII trialsGrowth mixture modellingTreatment expectationsLate respondersEarly respondersBaseline disease characteristicsTreatment of adultsSALT scoreWeek 52Baseline characteristicsClinical outcomesDisease characteristicsTreatment allocationHair lossPatientsResponse subgroupsRespondersSubgroupsClinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Ko J, Mayo T, Bergfeld W, Dutronc Y, Yu G, Ball S, Somani N, Craiglow B. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata. JAMA Dermatology 2023, 159: 970-976. PMID: 37556146, PMCID: PMC10413213, DOI: 10.1001/jamadermatol.2023.2581.Peer-Reviewed Original ResearchConceptsSevere alopecia areataSALT scoreAlopecia areataWeek 76Response rateWeek 52Week 36Pooled analysisHair lossLong-term extension dataEyebrow hair lossProportion of patientsWeeks of therapyClinician-reported outcomesHigh response rateHair loss scoreSelective JanusAdult patientsClinical outcomesOutcome scoresHair regrowthClinical trialsMAIN OUTCOMETreatment doseBaricitinib41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials
Craiglow B, Lee Y, Vañó-Galván S, Egeberg A, Dutronc Y, Durand F, Pierce E, Ding Y, Chen Y, Mostaghimi A. 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials. Journal Of The American Academy Of Dermatology 2023, 89: ab55. DOI: 10.1016/j.jaad.2023.07.224.Peer-Reviewed Original ResearchScalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials
Piraccini B, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen Y, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. Journal Of Dermatological Treatment 2023, 34: 2227299. PMID: 37381691, DOI: 10.1080/09546634.2023.2227299.Peer-Reviewed Original ResearchConceptsSevere alopecia areataHealth-related qualityHair regrowthAlopecia areataMinimal regrowthBaseline Hospital AnxietyProportion of patientsPhase 3 trialDepression Scale scoresGreater improvementBaricitinib 2Daily placeboMore patientsWeek 36Hospital AnxietyTreatment allocationSkindex-16PatientsScale scoreScore changePsychological symptomsPsychological burdenAreataTrialsScalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials
Piraccini B, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen Y, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials. SKIN The Journal Of Cutaneous Medicine 2023, 7: s186. DOI: 10.25251/skin.7.supp.186.Peer-Reviewed Original Research